Are PD-1 agonists finally on the verge of impacting inflammation?

It’s been 10 years since the first PD-1 inhibitor reached the market for cancer, and during all that time researchers have suspected that reversing the oncology mechanism through PD-1 agonism may help patients with inflammatory diseases. Several companies are now testing the notion. 

Phase IIa data from  Eli Lilly and Co. (NYSE:LLY) in rheumatoid arthritis were widely considered validating for the PD-1 agonist class, and at least six other companies have disclosed PD-1 agonist programs...